- Penumbra has had a better than expected 3rd quarter, and is well positioned to capitalise on a rebound in vascular and neurological procedures.
- The company has been a pioneer and advocate of mechanical thrombectomy in ischemic stroke patients, helping improve patient outcomes.
- The REAL platform, which integrates virtual reality into rehabilitation, has the potential to provide an enormous remedial breakthrough.
- In this vein, shares are trading at a significant premium to peers until sales growth drives a correction in valuation.
- We are bullish on the long-term outlook of the company, especially in their vascular and neurological rehab markets.
For further details see:
Penumbra: Unique Play For Virtual Reality Exposure In Medical Technology